Abbott Is Spinning Off Nutrition and Calling It Strength — The Same Call Cut the Guide
A tax-free separation, two businesses blaming LAA and CGM pricing, and a CEO who won't say where the litigation lands
ABT · Earnings Call · 2026-10-21
The spin that management insists is not a confession
Abbott used its third-quarter call to announce the separation of its nutrition business into an independent, publicly traded company via a tax-free distribution to shareholders, targeted for completion by the end of next year. The asset is real and large: roughly $8.5 billion of annual sales, 16,000 employees, 14 manufacturing sites, and iconic brands from Similac to Ensure, with Daniel Salvadori named CEO-designate. The Nutrition company would be, in Ford's words, the largest globally scaled pure-play in healthy nutrition, and management expects it to qualify for the S&P 500.
The framing is that this is offense, not retreat. “This decision follows a comprehensive strategic review and reflects our strong belief that both Abbott and the nutrition business can create greater value” — Robert Ford, Chairman and Chief Executive Officer · 2026-10-21. And Ford pre-emptively swatted at critics, a tell in itself:
I think I read a story that just came out, a headline that just came out on Barron's, who got it totally wrong. I'm just going to say it. It's coming out of a position of strength.
Why so defensive? Because for five straight quarters this was the problem child. In January the entire company guidance was trimmed largely on nutrition's volume problem — the Nutrition business keyword dominated that call, with Adult Nutrition pricing and reaccelerating volume growth as the fix. The separation and independent company language now topping Abbott's keyword set is genuinely new for this name; the strategic pivot is company-unique, not sector boilerplate.
The guide went the wrong way in the same breath
Buried under the spin headline: full-year comparable growth is now about 6%, implying just north of 8% for Q4, down from prior expectations. Ford attributed it to two businesses — electrophysiology and diabetes — and insisted it was a timing issue, not a reset: “it's just adjusting based on what we're seeing right now, which is EP and diabetes” — Robert Ford, Chairman and Chief Executive Officer · 2026-10-21.
Set that against three months ago, when the same CEO told the same analyst that the healthcare demand backdrop was intact — “testing volumes in the US have held up very well. Not seeing a decline” — Robert Ford, Chairman and Chief Executive Officer · 2026-07-16 — and against the July claim that 7% was a durable growth rate (“I believe 7% is still the right target” — Robert Ford, Chairman and Chief Executive Officer · 2026-07-16). Now 2027 is being framed as "pretty similar to this year," with management explicitly conceding a weaker top-line track record and opting for a conservative starting point. The acceleration in growth narrative that carried the first half of 2026 has quietly been pushed into a launch calendar.
The EP issue is subtle and interesting. Abbott's ablation business is accelerating, but its LAA device franchise is shrinking — and management says the mere CE Mark for the next-generation Amulet 360 caused U.S. accounts to stop ordering the current device while they wait. That is a self-inflicted air pocket from good news, worth about five points of EP growth (Q4 EP ~20% instead of ~25%).
Diabetes: the reimbursement that keeps not arriving
This is the sharpest reversal. In July, reimbursement expansion was the single highest-ranked keyword in Abbott's keyword set, and the promise was explicit: “any one of these markets that goes to reimbursement expansion... it drastically accelerates the growth rate as we have seen in the past” — Robert Ford, Chairman and Chief Executive Officer · 2026-07-16. Three months later, CGM is guided to low-to-mid single digits for the next several quarters, with international price concessions to defend 50–70% share and no CMS expansion in the plan: “when it does kick in, like we've seen this in the past, acceleration happens... Right now, what I can say is I'm not really factoring it in” — Robert Ford, Chairman and Chief Executive Officer · 2026-10-21. The reimbursement expansion theme has not disappeared — it has been demoted from catalyst to optionality.
Two balance sheets, one unanswered question
The financial mechanics of the split are deliberately vague: the new company will raise debt and distribute a portion of proceeds to Abbott, both will carry investment-grade ratings, and combined dividends will equal Abbott's current payout. Where the infant-formula litigation sits is undecided — “I'll provide more details of that as we progress in terms of exactly where the liability will sit” — Robert Ford, Chairman and Chief Executive Officer · 2026-10-21. Analysts asked twice. They got a promise, not an answer.
What is knowable is the shape of the balance sheet post-Exact Sciences. Effective net cash stands at −$27.0B, versus −$4.0B at the end of 2025, and interest coverage has fallen to 4.8x from nearly 20x. That is why the spin's debt raise matters, and why Ford's "net debt to EBITDA around 2 times" matters more than the growth math. Meanwhile the underlying P&L is improving: gross margin of 57.7% sits near the top of its multi-year range, adjusted gross margin rose 140bp to 57.2%, and R&D of $892M, up 23% year over year is the deliberate cost of the launch calendar. Strip nutrition out and management promises 50–100bp more growth and 200bp+ more gross margin.
The tape is not pricing a broken story
Abbott has run +13.4% in 90 days into this print — a clean single up-segment — yet sits 13.9% below its August 24 high of $116.67 and 28.9% under the 2021 peak. Valuation reflects the disillusionment: 3.4x price-to-revenue, down 39% year over year and 20.4x price-to-operating-income. The news flow in the window is uniformly dividend-king, buy-the-dip fare — the market's framing is defensive income, not growth.
That is the tension in one line: Abbott is spending the call celebrating a new company built "from a position of strength," while simultaneously lowering the growth bar, deferring a reimbursement catalyst it spent a year advertising, and declining to say who inherits its biggest legal liability. The spin may well create value. But this was a quarter of promises deferred disguised as a quarter of promises kept.